These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

964 related articles for article (PubMed ID: 25586400)

  • 1. Glutamate and dopamine in schizophrenia: an update for the 21st century.
    Howes O; McCutcheon R; Stone J
    J Psychopharmacol; 2015 Feb; 29(2):97-115. PubMed ID: 25586400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.
    de Bartolomeis A; Iasevoli F; Tomasetti C; Buonaguro EF
    Mol Neurobiol; 2015 Dec; 52(3):1771-1790. PubMed ID: 25394379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review.
    de Bartolomeis A; Barone A; Vellucci L; Mazza B; Austin MC; Iasevoli F; Ciccarelli M
    Mol Neurobiol; 2022 Oct; 59(10):6460-6501. PubMed ID: 35963926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.
    de Bartolomeis A; Fiore G; Iasevoli F
    Curr Pharm Des; 2005; 11(27):3561-94. PubMed ID: 16248808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.
    Demjaha A; Egerton A; Murray RM; Kapur S; Howes OD; Stone JM; McGuire PK
    Biol Psychiatry; 2014 Mar; 75(5):e11-3. PubMed ID: 23890739
    [No Abstract]   [Full Text] [Related]  

  • 7. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
    Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Pharmacological Targets for the Treatment of Schizophrenia: A Literature Review.
    Ventriglio A; Bellomo A; Ricci F; Magnifico G; Rinaldi A; Borraccino L; Piccininni C; Cuoco F; Gianfelice G; Fornaro M; Delle Monache S; De Berardis D
    Curr Top Med Chem; 2021 Oct; 21(16):1500-1516. PubMed ID: 34218785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.
    de Bartolomeis A; Buonaguro EF; Iasevoli F
    Psychopharmacology (Berl); 2013 Jan; 225(1):1-19. PubMed ID: 23179966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.
    Mouchlianitis E; Bloomfield MA; Law V; Beck K; Selvaraj S; Rasquinha N; Waldman A; Turkheimer FE; Egerton A; Stone J; Howes OD
    Schizophr Bull; 2016 May; 42(3):744-52. PubMed ID: 26683625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways.
    Perez SM; Lodge DJ
    Drug Des Devel Ther; 2014; 8():887-96. PubMed ID: 25061280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.
    Stone JM
    Curr Pharm Des; 2009; 15(22):2594-602. PubMed ID: 19689330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A biochemical theory of schizophrenia].
    Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
    Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia.
    Banerjee SP; Zuck LG; Yablonsky-Alter E; Lidsky TI
    Neuroreport; 1995 Dec; 6(18):2500-4. PubMed ID: 8741750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia.
    Zuo D; Bzdega T; Olszewski RT; Moffett JR; Neale JH
    J Biol Chem; 2012 Jun; 287(26):21773-82. PubMed ID: 22570482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schizophrenia: from dopamine to glutamate and back.
    Carlsson ML; Carlsson A; Nilsson M
    Curr Med Chem; 2004 Feb; 11(3):267-77. PubMed ID: 14965231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.